What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?

References

• Jadon DR, Sengupta R, Nightingale A, et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondylarthritis. Ann Rheum Dis. 2017;76(4):701–707.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–7.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Scriffignano S, Perrotta FM. Psoriatic arthritis, psoriatic disease, or psoriatic syndrome? J Rheumatol. 2019;46(11):1428–1430.
   PubMed Web of Science ®Google Scholar
• Scrivo R, D’Angelo S, Carriero A, et al. The conundrum of psoriatic arthritis: a pathogenetic and clinical pattern at the midpoint of autoinflammation and autoimmunity. Clin Rev Allergy Immunol. 2022. DOI:10.1007/s12016-021-08914-w.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Anhorn KA, Schachter RK, et al. HLA antigens in psoriatic arthritis. J Rheumatol. 1986;13(3):586–592.
   PubMed Web of Science ®Google Scholar
• FitzGerald O, Haroon M, Giles JT, et al. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015;17(1):115.
   PubMed Web of Science ®Google Scholar
• Reveille JD. The genetic basis of spondyloarthritis. Ann Rheum Dis. 2011;70(Suppl 1):i44–50.
   PubMed Web of Science ®Google Scholar
• Cafaro G, McInnes IB. Psoriatic arthritis: tissue-directed inflammation? Clin Rheumatol. 2018;37(4):859–868.
   PubMed Web of Science ®Google Scholar
• Cambre I, Gaublomme D, Burssens A, et al. Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis. Nat Commun. 2018;9(1):4613.
   PubMedGoogle Scholar
• Picchianti-Diamanti A, Rosado MM, D’Amelio R. Infectious agents and inflammation: the role of microbiota in autoimmune arthritis. Front Microbiol. 2017;8:2696.
   PubMed Web of Science ®Google Scholar
• Hsieh J, Kadavath S, Efthimiou P. Can traumatic injury trigger psoriatic arthritis? A review of the literature. Clin Rheumatol. 2014;33(5):601–608.
   PubMed Web of Science ®Google Scholar
• McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol. 2009;23:9–13.
   PubMed Web of Science ®Google Scholar
• Van Praet L, FE VDB, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;72(3):414–417.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ferrante A, Guggino G, et al. Gut inflammation in spondyloarthritis. Best Pract Res Clin Rheumatol. 2017;31(6):863–876.
   PubMed Web of Science ®Google Scholar
• Van Praet L, Jans L, Carron P, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014;73(6):1186–1189.
   PubMed Web of Science ®Google Scholar
• Kehl AS, Corr M, Weisman MH. Review: enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheumatol. 2016;68(2):312–322.
   PubMed Web of Science ®Google Scholar
• Lories RJ, de Vlam K. Is psoriatic arthritis a result of abnormalities in acquired or innate immunity? Curr Rheumatol Rep. 2012;14(4):375–382.
   PubMed Web of Science ®Google Scholar
• Jongbloed SL, Lebre MC, Fraser AR, et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther. 2006;8(1):R15.
   PubMed Web of Science ®Google Scholar
• Aochi S, Tsuji K, Sakaguchi M, et al. Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages. J Am Acad Dermatol. 2011;64(5):879–887.
   PubMed Web of Science ®Google Scholar
• Ross EA, Devitt A, Johnson JR. Macrophages: the good, the bad, and the gluttony. Front Immunol. 2021;12:3234.
   Web of Science ®Google Scholar
• Kabala PA, Malvar-Fernández B, Lopes AP, et al. Promotion of macrophage activation by tie2 in the context of the inflamed synovia of rheumatoid arthritis and psoriatic arthritis patients. Rheumatology. 2020;59(2):426–438.
   PubMed Web of Science ®Google Scholar
• Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol. 2003;30(2):260–268.
   PubMed Web of Science ®Google Scholar
• Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628–639.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(10):2095–2096.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–1076.
   PubMed Web of Science ®Google Scholar
• Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med. 2012;18(7):1018–1019.
   PubMed Web of Science ®Google Scholar
• Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2022;5:1–17.
   Google Scholar
• Tsukazaki H, Kaito T. The role of the IL-23/IL-17 pathway in the pathogenesis of spondyloarthritis. Int J Mol Sci. 2020;21(17):6401.
   PubMed Web of Science ®Google Scholar
• Schett G, Rahman P, Ritchlin C, et al. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022;18(6):311–325.
   PubMed Web of Science ®Google Scholar
• Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(4):217–233.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK- STAT pathway: impact on human disease and thera- peutic intervention. Ann Rev Med. 2015;66(1):311–328.
   PubMedGoogle Scholar
• Seif F, Khoshmirsafa M, Aazami H, et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017;15(1):23.
   PubMedGoogle Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–287.
   PubMed Web of Science ®Google Scholar
• Choy EH. Clinical significance of Janus kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953–962.
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537–1550.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525–1536.
   PubMed Web of Science ®Google Scholar
• Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–479.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Costa L, Atteno M, et al. Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother. 2013;14(17):2311–2313.
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D, Miossec P. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol. 2019;15(12):747–757.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Menter A, Mendelsohn A, et al. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin. 2010;26(10):2385–2392.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–789.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–999.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000–1006.
   PubMed Web of Science ®Google Scholar
• Araujo EG, Englbrecht M, Hoepken S, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48(4):632–637.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Ortolan A, Lorenzin M, et al. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clin Rheumatol. 2018;37(2):397–405.
   PubMed Web of Science ®Google Scholar
• Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–854.
   PubMed Web of Science ®Google Scholar
• Azuaga AB, Frade-Sosa B, Laiz A, et al. Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study. Clin Rheumatol. 2020;39(10):2963–2971.
   PubMed Web of Science ®Google Scholar
• Gossec L, Siebert S, Bergmans P, et al. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis. 2022;81(6):823–830.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and crohn’s disease: an integrated analysis of phase II/III clinical development programs. Drug Saf. 2019;42(6):751–768.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115–1125.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–1136.
   PubMed Web of Science ®Google Scholar
• Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359–369.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatol. 2021;60:2109–2121.
   PubMed Web of Science ®Google Scholar
• Pantano I, Mauro D, Romano F, et al. Real-life efficacy of guselkumab in patients with early psoriatic arthritis. Rheumatology (Oxford). 2022;61:1217–1221.
   PubMedGoogle Scholar
• Nakamura M, Lee K, Jeon C, et al. Guselkumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb). 2017;7(3):281–292.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase2 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2021;1–7.
   Google Scholar
• Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2021;1–8.
   Google Scholar
• Gargiulo L, Ibba L, Pavia G, et al. Real-Life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb). 2022;12(10):2309–2324.
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605–617.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Chohan S, Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021;80(9):1147–1157.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier (NCT number): NCT04314544.
   Google Scholar
• Menter A, Krueger GG, Paek SY, et al. Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb). 2021;11(2):385–400.
   PubMed Web of Science ®Google Scholar
• Cuthbert RJ, Watad A, Fragkakis EM, et al. Evidence that tissue resident human enthesis cdT-cells can produce IL-17A independently of IL-23R transcript expression. Ann Rheum Dis. 2019;78(11):1559–1565.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, D’Antonio A, Conigliaro P, et al. An update for the clinician on biologics for the treatment of psoriatic arthritis. Biologics. 2020;14:53–75.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Alten R, D’Agostino MA, et al. Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD Open. 2021;7(3):e001681.
   PubMed Web of Science ®Google Scholar
• Sakkas LI, Zafiriou E, Bogdanos DP. Mini review: new treatments in psoriatic arthritis. focus on the IL-23/17 axis. Front Pharmacol. 2019;10:872.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Reimold AM, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year follow up from a phase III, randomized, double-blind placebo-controlled study: psA and long-term treatment with secukinumab. Arthritis Care Res. 2017;69(3):347–355.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatol. 2017;56(11):1993–2003.
   PubMed Web of Science ®Google Scholar
• Mease P, Van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890–897.
   PubMed Web of Science ®Google Scholar
• Braun J, Blanco R, Marzo-Ortega H, et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021;23(1):231.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active- controlled, phase 3b trial. Lancet. 2020;395(10235):1496–1505.
   PubMed Web of Science ®Google Scholar
• Strand V, McInnes I, Mease P, et al. Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naïve patients with psoriatic arthritis. J Comp Eff Res. 2019;8(7):497–510.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Holko P, Mocko P, et al. Comparative effectiveness of Abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int. 2018;38(2):189–201.
   PubMed Web of Science ®Google Scholar
• Mourad A, Gniadecki R. Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and meta-analysis. J Rheumatol. 2019;47(1):59–65.
   PubMed Web of Science ®Google Scholar
• Elliott A, Wright G. Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19858510.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Keininger DL, Holdsworth EA, et al. Real world effectiveness and satisfaction with secukinumab in the treatment of patients with psoriatic arthritis: a population survey in five European countries. Curr Med Res Opin. 2021;37(10):1845–1853.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Fonti GL, Conigliaro P, et al. One-year effectiveness, retention rate and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther. 2020;20(7):813–821.
   PubMed Web of Science ®Google Scholar
• Fonti GL, Chimenti MS, Greco E, et al. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary. Clin Exp Rheumatol. 2021;39(1):223.
   PubMed Web of Science ®Google Scholar
• Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47–62.
   PubMed Web of Science ®Google Scholar
• Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018;179(5):1205–1207.
   PubMed Web of Science ®Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (Adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87.
   PubMed Web of Science ®Google Scholar
• Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–2327.
   PubMed Web of Science ®Google Scholar
• Kiltz U, Wei JC, van der Heijde D, et al. Ixekizumab improves functioning and health in the treatment of radiographic axial spondyloarthritis: week 52 results from 2 pivotal studies. J Rheumatol. 2021;48(2):188–197.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Mease P, Rahman P, et al. Ixekizumab improves patient-reported outcomes in non-radiographic axial spondyloarthritis: results from the coast-X trial. Rheumatol Ther. 2021;8(1):135–150.
   PubMed Web of Science ®Google Scholar
• Coates LC, Pillai SG, Tahir H, et al. Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study. Arthritis Rheumatol. 2021;73(9):1663–1672.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and Adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79:123–131.
   PubMed Web of Science ®Google Scholar
• Giunta A, Ventura A, Chimenti MS, et al. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. Drug Des Devel Ther. 2017;11:1643–1651.
   PubMed Web of Science ®Google Scholar
• Manfreda V, Chimenti MS, Canofari C, et al. Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting. Clin Exp Rheumatol. 2020;38(3):581–582.
   PubMed Web of Science ®Google Scholar
• Murage MJ, Princic N, Park J, et al. Real-world treatment patterns and healthcare costs in patients with psoriatic arthritis treated with ixekizumab: a retrospective study. ACR Open Rheumatol. 2021;3(12):879–887.
   PubMedGoogle Scholar
• Darabian S, Badii M, Dutz JP, et al. A retrospective study on the effectiveness of ixekizumab after treatment with secukinumab for patients with active psoriatic arthritis. J Psoriasis Psoriatic Arthritis. 2022;7(1):13–16.
   Google Scholar
• Navarini L, Currado D, Costa L, et al. Experimental and investigational pharmacotherapy for psoriatic arthritis: drugs of the future. J Exp Pharmacol. 2020;12:487–502.
   PubMedGoogle Scholar
• Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs. 2012;4(2):182–197.
   PubMed Web of Science ®Google Scholar
• Freitas E, Blauvelt A, Torres T. Bimekizumab for the treatment of psoriasis. Drugs. 2021;81(15):1751–1762.
   PubMed Web of Science ®Google Scholar
• Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized igg1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–486.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–498.
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus Adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130–141.
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–152.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427–440.
   PubMed Web of Science ®Google Scholar
• Oliveira DG, Faria R, Torres T. An overview of bimekizumab for the treatment of psoriatic arthritis: the evidence so far. Drug Des Devel Ther. 2021;15:1045–1053.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Asahina A, Gladman DD, et al. Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. Rheumatology (Oxford). 2022;keac353. DOI:10.1093/rheumatology/keac353.
   PubMedGoogle Scholar
• ClinicalTrials.gov identifier (NCT number): NCT03896581.
   Google Scholar
• ClinicalTrials.gov identifier (NCT number): NCT03895203.
   Google Scholar
• ClinicalTrials.gov identifier (NCT number): NCT04009499.
   Google Scholar
• Bellinato F, Gisondi P, Girolomoni G. Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules. Biologics. 2021;15:247–253.
   PubMed Web of Science ®Google Scholar
• Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570.
   PubMedGoogle Scholar
• Lebwohl M, Leonardi C, Armstrong A, et al. Three-year U.S. pharmacovigilance report of brodalumab. Dermatol Ther. 2021;34(6):e15105.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Helliwell PS, Hjuler KF, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2021;80(2):185–193.
   PubMed Web of Science ®Google Scholar
• Rusta-Sallehy S, Gooderham M, Papp K. Brodalumab: a review of safety. Skin Therapy Lett. 2018;23(2):1–3.
   PubMedGoogle Scholar
• Reich K, Thaçi D, Stingl G, et al. Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials. Acta Derm Venereol. 2022;102:adv00683.
   PubMed Web of Science ®Google Scholar
• Valenti M, Pavia G, Gargiulo L, et al. Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single-center real-life population. J Dermatolog Treat. 2022;33(3):1638–1642.
   PubMed Web of Science ®Google Scholar
• Campanaro F, Batticciotto A, Zaffaroni A, et al. JAK inhibitors and psoriatic arthritis: a systematic review and meta-analysis. Autoimmun Rev. 2021;20(10):102902.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Accordi B, Martini V, et al. JAK/STAT/PKCdelta molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res. 2014;58(1):61–69.
   PubMed Web of Science ®Google Scholar
• Berekmeri A, Mahmood F, Wittmann M, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719–730.
   PubMed Web of Science ®Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Tofacitinib or Adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019;5(1):e000806.
   PubMed Web of Science ®Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL beyond. RMD Open. 2019;5(1):e000808.
   PubMed Web of Science ®Google Scholar
• Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study. Rheumatol Ther. 2020;7(3):553–580.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or Adalimumab. J Rheumatol. 2019;46(9):1089–1096.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Coates LC, Wu J, et al. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, Adalimumab, or placebo. Arthritis Res Ther. 2022;24(1):401.
   Web of Science ®Google Scholar
• Mease PJ, Young P, Gruben D, et al. Early real-world experience of tofacitinib for psoriatic arthritis: data from a United States healthcare claims database. Adv Ther. 2022;39(6):2932–2945.
   PubMed Web of Science ®Google Scholar
• Orbai AM, Mease PJ, Helliwell PS, et al. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies. BMC Rheumatol. 2022;6(1):68.
   PubMedGoogle Scholar
• Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021;7(2):e001595.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Curtis JR, Yamaoka K, et al. Clinical management of herpes zoster in patients with rheumatoid arthritis or psoriatic arthritis receiving tofacitinib treatment. Rheumatol Ther. 2022;9(1):243–263.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021;7(3):e001838.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020;80(3):312–320.
   PubMed Web of Science ®Google Scholar
• Muensterman E, Engelhardt B, Gopalakrishnan S, et al. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials. Clin Transl Sci. 2022;15(1):267–278.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227–1239.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Winthrop K, Blanco R, et al. Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials. Rheumatol Ther. 2022;9(2):521–539.
   PubMed Web of Science ®Google Scholar
• Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191(7):3568–3577.
   PubMed Web of Science ®Google Scholar
• Robin-Jagerschmidt C, Lavazais S, Marsais F, et al. OP0161 The JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis. Ann Rheum Dis. 2017;76:118–119.
   Web of Science ®Google Scholar
• Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2367–2377.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76(6):1009–1019.
   PubMed Web of Science ®Google Scholar
• Hellstrom WJG, Dolhain RJEM, Ritter TE, et al. MANTA and MANTA-RAy: rationale and design of trials evaluating effects of filgotinib on semen parameters in patients with inflammatory diseases. Adv Ther. 2022;39(7):3403–3422.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier (NCT number): NCT03926195.
   Google Scholar
• Orr C, Veale DJ. Is there a need for new agents with novel mechanisms of action in psoriatic arthritis? Ann Rheum Dis. 2014;73(6):951–953.
   PubMed Web of Science ®Google Scholar
• Sun S, Ding Z, Yang X, et al. Nanobody: a small antibody with big implications for tumor therapeutic strategy. Int J Nanomedicine. 2021;16:2337–2356.
   PubMed Web of Science ®Google Scholar
• Puig L, Bakulev AL, Kokhan MM, et al. Efficacy and safety of netakimab, a novel anti-il-17 monoclonal antibody, in patients with Moderate to severe plaque psoriasis. results of a 54-week randomized double-blind placebo-Controlled PLANETA clinical trial. Dermatol Ther (Heidelb). 2021;11(4):1319–1332.
   PubMed Web of Science ®Google Scholar
• Korotaeva T, Gaydukova I, Mazurov V, et al. Netakimab decreases disease activity in patients with psoriatic arthritis: results from a randomized double-blind phase 3 clinical trial (PATERA). Ann Rheum Dis. 2020;79(Suppl 1):141–142.
   PubMedGoogle Scholar
• ClinicalTrials.gov identifier (NCT number): NCT03447704.
   Google Scholar
• Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Ther Adv Chronic Dis. 2021;12:20406223211037846.
   Web of Science ®Google Scholar
• Papp KA, Weinberg MA, Morris A, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021;397(10284):1564–1575.
   PubMed Web of Science ®Google Scholar
• Mansikka H, Ruzek M, Hugunin M, et al. FRI0164 safety, tolerability, and functional activity of ABT-122, a dual TNF- and IL-17A–targeted DVD-IG, following single-dose administration in healthy subjects. Ann Rheum Dis. 2015;74(Suppl 2):482–483.
   Google Scholar
• Mease PJ, Genovese MC, Weinblatt ME, et al. Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate. Arthritis Rheumatol. 2018;70(11):1778–1789.
   PubMed Web of Science ®Google Scholar
• Salimi S, Yamauchi PS, Thakur R, et al. Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: a narrative review. Dermatol Ther. 2020;33(4):e13800.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier (NCT number): NCT03482011.
   Google Scholar
• ClinicalTrials.gov identifier (NCT number): NCT03535194.
   Google Scholar
• Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736.
   PubMed Web of Science ®Google Scholar
• Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–351.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Strober B, Gordon KB, et al. Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial. Dermatol Ther (Heidelb). 2022;12(2):495–510.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815–822.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier (NCT number): NCT04908202.
   Google Scholar
• ClinicalTrials.gov identifier (NCT number): NCT04908189.
   Google Scholar
• ClinicalTrials.gov identifier (NCT number): NCT03963401.
   Google Scholar